Clinical Trial Update: Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating capecitabine and lapatinib ditosylate in various forms of head and neck squamous cell carcinoma has completed with posted resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Salivary Gland Squamous Cell Carcinoma
• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Lip and Oral Cavity
• Squamous Cell Carcinoma of the Oropharynx
• Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
• Verrucous Carcinoma of the Larynx
• Verrucous Carcinoma of the Oral Cavity

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib Ditosylate (lapatinib ditosylate)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-19